BARDA’s commitment to investing in pharmaceutical manufacturing and supply chain resilience
BARDA is making critical investments to accelerate the expansion of domestic manufacturing capacity for ancillary supplies (e.g., needles, syringes, vials) as part of our commitment to foster and expand domestic pharmaceutical manufacturing.
BARDA is making critical next-generation and continuous manufacturing investments to drive innovation in manufacturing.
BARDA is investing in the domestic industrial base to sustain the manufacturing capacity for raw materials, critical ingredients, consumables, and facilities required to produce COVID-19 (and future) vaccines and therapeutics.
